RECOMMENDATIONS FOR THE PREVENTION, DETECTION, AND CONTROL OF INFLUENZA IN CALIFORNIA LONG-TERM CARE FACILITIES, 2006-2007

California Department of Health Services
Division of Communicable Disease Control
In Consultation with Licensing and Certification Program

850 Marina Bay Parkway
Richmond, California 94804

October 2006

ARNOLD SCHWARZENEGGER
Governor
State of California

Kimberly Belshé, Secretary
Health and Human Services Agency

Sandra Shewry, Director
Department of Health Services
This report updates the 2005-2006 recommendations regarding the prevention, detection, and control of influenza outbreaks in California long-term healthcare facilities. These recommendations were developed by the California Department of Health Services (CDHS), Division of Communicable Disease Control, using information from the Centers for Disease Control and Prevention (CDC), in consultation with the Licensing and Certification Program, and are revised annually. This information is intended to be advisory only and was developed to assist facility infection control committees in the development of a rational approach to the control of influenza in long-term healthcare facilities (LTCFs).


Table of Contents

I. Influenza and Influenza-Like Illness 2
II. The Influenza Season in California Last Year 2
III. Transmission of Influenza 3
IV. Influenza Vaccine 3
V. Will There Be Enough Influenza Vaccine This Year? 4
VI. Laboratory Diagnosis of Influenza 5
VII. Infection Prevention and Control Precautions for Seasonal Influenza and Other Respiratory Infections 5
VIII. Outbreak Control Procedures for Influenza and Influenza-like Respiratory Infections 8
IX. Antiviral Drugs for the Control of Influenza Outbreaks 9

References and Other Sources of Information 12

Appendix 1. Sample Influenza Declination Form ................................................................. 13
Appendix 2. Sample Case Log of Residents with Acute Respiratory Illness and/or Pneumonia .......................................................................................................................... 14
Appendix 3. Sample Case Log of Staff with Acute Respiratory Illness and/or Pneumonia 15
Appendix 4. Sample Summary Log of Acute Respiratory Illness and Pneumonia .............. 16
Appendix 5. Sample Line List of Residents with Adverse Reactions to Anti-Influenza Medication ...................................................................................................................... 17
Appendix 6. Antiviral Drugs ................................................................................................. 18

Table 1. Recommended adult1 daily dosage of antiviral medication for treatment and prophylaxis 24
I. Influenza and Influenza-Like Illness

Influenza, commonly called “the flu”, is a respiratory illness caused by influenza type A or type B viruses. Typical symptoms of influenza include fever, respiratory symptoms (such as cough, sore throat, and other “cold” symptoms), muscle aches and headache. Persons with acute onset of fever and cough, often with nasal congestion, are most likely to have influenza. However, elderly long-term care residents, particularly those with underlying illness, may not have typical symptoms, such as a fever. Some have underlying conditions or are receiving medications with antipyretic (anti-fever) effects that modify the manifestations of influenza. Many also have chronic cough and other respiratory symptoms due to chronic lung disease. Some cannot reliably report symptoms such as sore throat or muscle aches. Therefore, the presentation of influenza in long-term care residents is not consistent or predictable. Influenza should be considered (particularly during influenza season) in residents with any combination of the following:

- Fever ≥ 37.8°C (may be absent or low in elderly long-term care residents)
- New onset cough and/or sore throat
- Nasal congestion
- Malaise (feeling ill)
- Chills
- Muscle aches, joint aches, or headache
- Change in respiratory status (increased cough, sputum production, breathing rate); change in mental status or appetite

Other respiratory viruses and some bacteria can cause similar illness, particularly in elderly LTCF residents. These are referred to as “influenza-like illness.” The difference between influenza and other acute respiratory infections cannot be determined on the basis of symptoms alone; laboratory testing is necessary (see Section VI).

Most young, healthy people who get influenza recover completely within 1-2 weeks. Influenza is a particularly serious problem in nursing homes. Because of their age and chronic health problems, nursing home residents are at high risk of developing serious complications or dying when they get influenza. They may also be at high risk of exposure to influenza, since the virus spreads easily in environments where people live close to each other. Once the virus enters a nursing home, it can spread rapidly. Influenza typically occurs annually in the winter between October and April; peak activity in a community usually lasts from 6 to 8 weeks, often spanning the New Year period. These recommendations are being issued in anticipation of possible influenza outbreaks in California long-term care facilities this season.

II. The Influenza Season in California Last Year

Overall, influenza activity in the 2005-2006 influenza season was moderate in severity. The magnitude of influenza activity in California was higher than 2004-2005, but comparable to previous years. The season was marked by a large peak in weeks 51-52 (due mostly to influenza A) followed by a smaller peak spread out over weeks 1-16 of 2006 (due to a mixture of influenza A and B). As in 2004-05, the “A/California” strain accounted for most of the influenza virus in California and the U.S. Last season a new strain evolved
Recommendations For Influenza in Long-Term Care Facilities 2006-2007

from “A/California” that was identified as “A/Wisconsin”, which has been included in the 2006-07 influenza vaccine. However, even with optimal matches outbreaks can still occur among vaccinated groups, especially in the elderly.

In January 2006, high national levels (>95%) of influenza resistance to the antiviral drugs amantadine and rimantadine (known together as adamantanes) were reported. In a subset of specimens collected from California residents last season, 96% also demonstrated resistance to the same drugs. Information on influenza activity in California can be accessed at http://www.dhs.ca.gov/ps/dc/VRDL/html/FLU/Fluintro.htm, and for the United States at www.cdc.gov/ncidod/diseases/flu/weeklychoice.htm.

III. Transmission of Influenza

Influenza is spread from person-to-person by large droplets of respiratory secretions from an infected person. This occurs when infected persons cough, sneeze, or talk, expelling droplets, which are then directly deposited onto the surfaces of the upper respiratory tracts (nose, throat) of susceptible persons who are within approximately 3 feet of the infected person. Transmission also may occur by direct or indirect (person-object-person) contact, when a susceptible person picks up the virus on their hands and then touches their nose. Influenza virus can survive for 24-48 hours on nonporous surfaces and 8-12 hours on porous surfaces such as paper or cloth. Airborne transmission, inhalation of small droplets (droplet nuclei) expelled into the air by an infected person coughing, may also occur. The degree to which airborne transmission contributes to influenza transmission is uncertain and has not been adequately studied.

The most important sources of influenza virus are infected persons. Infected persons are most infectious during the first 3 days of illness; however, they can shed the virus beginning the day before, and up to 7 or more days after, onset of symptoms. Children and severely immunodeficient persons may shed virus for longer periods. In addition, infected but asymptomatic persons can shed the virus and be infectious.

IV. Influenza Vaccine

Vaccination is the most effective measure for reducing the illness and deaths from influenza. All residents and staff should be vaccinated against influenza each autumn, beginning in October, before influenza disease is present in the community. A federal rule requires nursing homes serving Medicare and Medicaid (Medi-Cal) patients to provide immunizations against influenza and pneumococcal disease to all residents if they want to continue in the programs. Assembly Bill 1711, signed into law in August 2005, permits standing orders in California for residents of skilled nursing facilities aged 50 years or older to receive influenza and pneumococcal vaccination. Skilled nursing facilities should ensure that they comply with the new federal requirements by issuing standing orders for all residents aged 50 years or older to receive annual influenza vaccination and pneumococcal vaccination upon admission. Residents admitted during the winter months should be vaccinated when they are admitted. Information on methods of reimbursement for influenza and pneumococcal vaccine are available from the National Immunization Program in “Prevention and Control of Vaccine-Preventable Diseases in Long-Term Care Facilities,” accessible at (http://www.cdc.gov/nip/publications/Long-term-care.pdf).
Since the primary source of infection to residents is staff, and the efficacy of vaccination is often reduced in elderly residents, facilities should make a concerted effort to ensure the annual vaccination of staff, also beginning in October. Two recent studies have shown that staff vaccination reduces deaths from respiratory infections in residents. Vaccination can also lower staff absenteeism. California Senate Bill 739 was signed in September 2006; beginning July 2007 acute care hospitals will be required to offer influenza vaccine to employees free of charge and require those declining vaccination to sign a declination form. This is recommended for use in long-term care facilities that offer vaccine to their employees as a means to increase employee vaccination rates; an example is provided in Appendix 1.

FluMist®, the nasal-spray flu vaccine, is an option for healthy individuals, ages 5 to 49 years of age, and may be used as a substitute for standard flu vaccine for healthcare workers in long-term care facilities. FluMist® is a live, attenuated influenza vaccine (LAIV). LAIV is not recommended for healthcare workers taking care of severely immunocompromised people when they are in a protective environment, such as a hospital transplant unit, and cannot be given to pregnant women. LAIV is also not recommended for residents of long-term care facilities, since it is contraindicated for:

- persons aged <5 years or those aged >50 years;
- persons with asthma, reactive airways disease, or other chronic disorders of the pulmonary or cardiovascular systems; persons with other underlying medical conditions, including such metabolic diseases as diabetes, renal dysfunction, and hemoglobinopathies; or persons with known or suspected immunodeficiency diseases or who are receiving immunosuppressive therapies.

LAIV should not be administered until 48 hours after cessation of influenza antiviral therapy, and influenza antiviral medications should not be administered for 2 weeks after receipt of LAIV. LAIV should not be given within 4 weeks of another live vaccine. In addition, persons with the certain conditions should NOT be vaccinated with LAIV.

If a staff member is pregnant, a new law regarding thimerosal, effective July 1, 2006, limits administration of some vaccine formulations because of their level of the mercury-containing preservative, thimerosal [Health and Safety (H&S) Code Section 124172, Chapter 837, Statutes of 2004 (AB 2943, Pavley)]. Effective July 1, 2006, women who are "knowingly pregnant" (or children younger than 3 years old) may only receive vaccine doses that contain trace levels or no mercury. Vaccines given to pregnant women or to children under the age of 3 years in California may not exceed 1.0 microgram of mercury per 0.5 milliliters of influenza vaccine. See www.getimmunizedca.org for more information on the Thimerosal law.

V. Will There Be Enough Influenza Vaccine This Year?

The Centers for Disease Control and Prevention announced on September 7, 2006, that it expects a record 100 million influenza vaccines to be available for 2006-2007 after two years of temporary shortages and distribution problems. Vaccination recommendations are not expected to be limited to those in high-priority groups. Manufacturers began to ship this season's influenza vaccine in September, with almost all of the vaccine expected to be shipped and distributed in October and November. Up to date information and recommendations can be obtained at http://www.dhs.ca.gov/ps/dcic/izgroup/flu.htm and http://www.cdc.gov/flu/. The toll-free CDHS Flu Vaccine Information Line is 866-470-3788.
VI. Laboratory Diagnosis of Influenza

A person with influenza may not appear or feel different than when infected with many other respiratory pathogens. However, during outbreaks where influenza has been confirmed through laboratory tests, it can be presumed that other persons with similar symptoms also have influenza. Therefore, when a cluster of cases of acute respiratory illness with symptoms suggestive of influenza (see Section I above) occurs, it is of critical importance to try to establish the diagnosis through laboratory testing. When an outbreak of respiratory illness begins in a nursing home or any healthcare facility, the local health department and Licensing and Certification district office must be notified (California Code of Regulations, Title 22, Sections 72539 and 72541). Health department personnel can provide information about influenza activity in the area and about diagnostic specimen collection and coordination.

Several commercial rapid diagnostic tests are available that can detect influenza viruses within 30 minutes. Some of these rapid tests detect only influenza A viruses, whereas other rapid tests detect both influenza Type A and B viruses but do not distinguish between the two types. These tests can be performed on nasopharyngeal-swab or nasal-wash specimens. This information can then be used to determine if influenza antiviral drug therapy should be implemented to prevent the outbreak from spreading. Precise identification of the strain of virus can be made by growing the virus from nasopharyngeal secretions of acutely ill persons. Viral culture and molecular tests are available at the California Department of Health Services Viral and Rickettsial Disease Laboratory and some local health departments for the investigation of outbreaks.

VII. Infection Prevention and Control Precautions for Seasonal Influenza and Other Respiratory Infections

The implementation of infection prevention measures for influenza-like respiratory infections, which includes seasonal influenza, can prevent their spread in long-term care health facilities. Although vaccinating all facility personnel and residents is a primary influenza control measure, outbreaks of influenza and other viruses which mimic influenza can be prevented if the following recommendations are implemented as soon as possible to prevent person-to-person transmission.

A. Vaccination, Education, Monitoring

- Develop an influenza or influenza-like illness outbreak management plan that includes vaccination for seasonal influenza and use of the influenza vaccine declination form (Appendix 1, page 13).
- Vaccinate all residents and personnel working in the facility as soon as possible after the influenza vaccination has been distributed (October–November).
- Provide education about the facility respiratory hygiene/cough etiquette program (below) and reporting signs and symptoms of influenza and influenza-like respiratory infections to residents, facility personnel, visitors and volunteers at least annually and when influenza-like respiratory infections are identified in the facility.
• Monitor residents and facility personnel for symptoms of respiratory infection, especially during the influenza season (October to April).
• If influenza or influenza-like respiratory illnesses are suspected, promptly contact the local health department and request assistance with viral testing.

B. Respiratory Hygiene/Cough Etiquette

Respiratory hygiene/cough etiquette procedures should be implemented at the first point of contact with a potentially infected person to prevent the transmission of all respiratory tract infections in health-care settings (www.cdc.gov/flu/professionals/infectioncontrol/resphygiene.htm). Respiratory hygiene/cough etiquette programs include:

• Posting visual alerts instructing residents, staff, visitors and volunteers to report symptoms of respiratory infection to the infection control practitioner.
• Providing tissues or masks to visitors who are coughing or sneezing so that they can cover their nose and mouth.
• Ensuring that supplies for hand washing are available where sinks are located; or providing dispensers of alcohol-based hand rubs.
• Encouraging coughing persons to remain at least 3 feet away from others, if possible.

C. Infection Control Precautions for Residents with Influenza-Like Illness

• As soon as one or more residents develop an influenza-like acute respiratory illness (see Section I), confine the symptomatic resident(s) and exposed roommate(s) to their room, restrict them from group activities, and serve meals in their rooms.
• If new cases on the same nursing unit are identified, cancel group activities and serve all meals in resident’s rooms.
• Avoid rotating health-care workers between nursing units until no new cases have been identified for at least 5 days.
• Consider restricting the admission of new and returning residents. If admissions are necessary admit to the nursing units with asymptomatic residents.
• Wear a surgical or procedure mask when within 3 feet of symptomatic residents or when entering the resident’s room.
• Place a surgical or procedure mask over the resident’s nose and mouth, if tolerated, when transport or movement of the resident is necessary.
• Instruct residents to use tissues to cover their nose and mouth when coughing and sneezing. Provide a bag or other waste receptacle conveniently located for disposal of contaminated tissues.
• Wash or sanitize resident’s hands with an alcohol-based hand hygiene product frequently throughout the day, before leaving their room and after hand contact with respiratory secretions and contaminated tissues.
D. Health-Care Worker Infection Control Precautions

- Wear gloves when contact with the resident or contaminated environmental surfaces or objects in close vicinity to the resident is anticipated. Keep a supply of gloves in the resident’s room.
- Wear gowns when providing direct resident care.
- Change gloves and gowns after each resident encounter and perform hand hygiene.
- Wear a surgical or procedure mask upon entering the resident’s room or when working within 3 feet of the coughing, sneezing resident. Remove the mask upon leaving the resident’s room and dispose in a waste receptacle.
- Wash or sanitize hands before and after touching the resident, after touching environmental surfaces and items potentially contaminated with respiratory secretions, whether or not gloves are worn. If hands are not visibly soiled, use an alcohol-based hand rub for routine decontamination of hands. Alternatively, wash hands with soap (either plain or antimicrobial) and water.
- Advise staff to not work in other facilities (i.e. a second job) when ill with a respiratory illness. During a facility outbreak, facility personnel should not work at another facility until the local health department has determined that the outbreak is controlled.
- Implement enhanced environmental cleaning of commonly touched surfaces such as door handles, hallway banisters, toilet or bath rails, bedrails, overbed tables, nursing station counters.

E. Visitors Precautions

- Post signs discouraging visitors including children with any symptomatic respiratory infection including seasonal influenza from visiting residents.
- Provide written information about influenza-like infections and seasonal influenza to visitors and why the infection control precautions are necessary.
- Provide visitors with written instructions (respiratory hygiene/cough etiquette) about the precautions implemented by the facility.
- Encourage visitors to get vaccinated for influenza.
- If visitation is necessary instruct symptomatic visitors to (1) wear a surgical or procedure mask over their mouth and nose while in the resident’s room; (2) cough and sneeze into a tissue and discard contaminated tissues a waste receptacle; and (3) sanitize their hands before entering the resident’s room, before and after resident contact and upon leaving the resident’s room.
- Ensure that hand hygiene, tissues and masks are available.
VIII. Outbreak Control Procedures for Influenza and Influenza-like Respiratory Infections

A. Surveillance

- Suspect an outbreak when two (2) or more cases of acute respiratory infection (with or without fever) occur within 48-72 hours, particularly in residents who are in close proximity to each other (e.g. on the same nursing unit). An outbreak is a sudden increase in the number of cases of acute respiratory infection over the normal background rate or when any resident tests positive for influenza virus.

B. Confirm Diagnosis by Laboratory Testing

- The first three to four residents and/or health-care workers suspected of influenza or influenza-like respiratory infection (acute respiratory infection with or without fever) should have specimens obtained for laboratory testing.
- Contact the local health department for appropriate diagnostic laboratory test recommendations. If rapid antigen tests and/or viral cultures are recommended, determine the appropriate laboratory to process the specimens.

C. Collect, Analyze and Report Data

- Initiate the daily active surveillance log (Appendix 2, page 14) and collect data of all new symptomatic residents and facility personnel.
- Monitor facility personnel absenteeism due to influenza-like respiratory symptoms.
- Report all resident(s) and facility personnel with symptoms of influenza-like infection to the infection prevention and control practitioner (ICP). New cases should be reported and recorded daily using the case log (Appendix 2, page 14).
- Analyze reports of resident and facility personnel illness submitted by the nursing unit and other departments (environmental services) daily.
- Determine the infection attack rates for residents and facility personnel (# of infected residents/total number of vaccinated and total of non-vaccinated residents) and (# total number of infected facility personnel/total number of vaccinated and the total number of non-vaccinated facility personnel).
- Report data to the quality assurance/infection control committee and the Licensing and Certification district office with jurisdiction over the facility. (See notification).
- Review the infection surveillance and outbreak management plan to determine necessary revisions.
- Make revisions for implementing the outbreak management plan and influenza vaccination during the next influenza year.
D. Outbreak Notification

- Notify the facility medical director immediately.
- Notify the local health department and the Licensing and Certification district office with jurisdiction over your facility (www.dhs.ca.gov/lnc/org/default.htm).

E. Vaccination

- Vaccinate unvaccinated facility personnel and residents as soon as possible and consult with the local health department to determine if revaccination of facility personnel and/or residents during the outbreak would be beneficial.

6. Antiviral Drugs

- Consider the use of antiviral prophylaxis.

IX. Antiviral Drugs for the Control of Influenza Outbreaks.

Antiviral drugs for influenza are an important addition to influenza vaccine for the control of influenza outbreaks. While they are not a substitute for vaccination, they should be considered for use when influenza occurs in a population of unvaccinated persons. Four currently licensed agents are available in the United States: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine and rimantadine have been used for treatment and prophylaxis of influenza type A. However, recent evidence indicates that a high proportion of currently circulating influenza A viruses in California and in the United States have developed resistance to amantadine and rimantadine (together known as adamantanes). Therefore, neither amantadine nor rimantadine should be used for the treatment or prophylaxis of influenza A in the United States, and further reference to these drugs (together called adamantanes) has been removed from this guideline.

Oseltamivir and zanamivir (together called neuraminidase inhibitors) are effective against both type A or B influenza. Oseltamivir and zanamivir can both be used for treatment and chemoprophylaxis of influenza. Both medications can reduce the duration of uncomplicated influenza A and B illness by about one day compared with placebo. It is recommended to start antiviral treatment within 2 days of illness onset. The recommended duration of treatment is 5 days with either medication. Oseltamivir is currently approved for treatment of persons aged ≥ 1 year, and zanamivir is approved for treatment of persons aged ≥ 7 years.

Oseltamivir and zanamivir can both be used for chemoprophylaxis of influenza. Oseltamivir is licensed for use in persons aged ≥ 1 year, and zanamivir is licensed for use in persons ≥ 5 years. The timing and duration to administer antiviral medications for chemoprophylaxis should consider the cost, compliance, and potential side effects. For maximal results, the chemoprophylaxis medication should be taken each day for the duration of influenza activity at the site. For additional information on anti-influenza drugs see Appendix 6, page 18.
When outbreaks of influenza occur in a long-term care facility, and antiviral prophylaxis of high-risk persons and treatment of cases is undertaken, drug administration should begin as early in the outbreak as possible to reduce transmission. Contingency planning is needed to ensure immediate availability and rapid administration of the drugs. This might include obtaining prior approval from personal physicians for administration of antiviral drugs to residents in the event of an outbreak. Since it is difficult to know in advance how long antiviral drugs will need to be administered, some nursing homes have a policy that also allows facility staff or a consultant to decide when they should be discontinued.

When institutional outbreaks occur, chemoprophylaxis should be administered to all residents - regardless of whether they received influenza vaccine during the previous fall - and should continue for at least 2 weeks or until approximately 1 week after the end of the outbreak. The dosage for each resident should be determined individually (see Table 1). Chemoprophylaxis also can be offered to unvaccinated staff that provide care to persons at high risk. Prophylaxis should be considered for all employees, regardless of their vaccination status, if the outbreak is caused by a variant strain of influenza that is not well matched by the vaccine.

To limit the potential transmission of drug-resistant virus during institutional outbreaks, whether in chronic or acute-care settings or other closed settings, measures should be taken to reduce contact as much as possible between persons taking antiviral drugs for treatment and other persons, including those taking chemoprophylaxis.

1. Immediately upon confirmation of influenza, consider the use of antivirals prevent further spread of influenza viruses.

   a. Immediately upon confirmation of influenza A or B, consider the use of oseltamivir or zanamivir.

      i. Zanamivir or oseltamivir can be used for the treatment of both influenza A and B infections. Zanamivir and oseltamivir can reduce the duration of influenza symptoms when started **within the first 2 days of illness onset**. For treatment, zanamivir is administered as 2 oral inhalations twice a day for 5 days, and oseltamivir is administered twice a day orally. For chemoprophylaxis, zanamivir is administered as 2 oral inhalations once a day for 5 days, and oseltamivir is administered once a day orally. The dosage of oseltamivir may need to be decreased for those with impaired renal function. (See Table 1 Appendix 6, page 24 for additional dosing information).

      ii. Oseltamivir and zanamivir have both been approved for prophylaxis, community studies of healthy adults indicate that both drugs are about 80-85% effective in preventing influenza illness. **Chemoprophylaxis should be administered to all residents in the case of an outbreak and should continue for a minimum of 2 weeks.** If surveillance indicates that new cases continue to occur, chemoprophylaxis should be continued until approximately 1 week after the end of the outbreak. Chemoprophylaxis can be offered to unvaccinated staff members (or staff vaccinated less than 2 weeks prior to the outbreak) who provide care to persons at high risk. Antivirals may be considered for prophylaxis of all nursing home staff, regardless of their vaccination status, if the outbreak is suspected to be caused by a strain of influenza virus that is not well-matched to the vaccine.
b. Separate symptomatic residents on antiviral treatment from others to the extent possible in the facility to decrease the possibility of transmitting antiviral-resistant influenza.

c. Monitor adverse reactions to antivirals using the format of Appendix 5, page 17. Side effects can include bronchospasm (zanamivir) as well as gastrointestinal disturbances (oseltamivir).

d. Zanamivir is not recommended for treatment for patients with underlying airway disease (e.g., asthma, chronic obstructive pulmonary disease). If physicians choose to prescribe zanamivir to patients with underlying chronic respiratory disease after considering potential risks and benefits, the medication should be used with caution under conditions of appropriate monitoring and supportive care, including short-acting bronchodilators (See Appendix 6 for more details).

e. When considering use of antiviral medications, clinicians must consider the patient’s age, weight, and renal function (see Table 1 Appendix 6, page 24).

f. Exercise precaution when administering oseltamivir or zanamivir to persons with:
   - Decreased renal function (adjust the dose based on creatinine clearance for oseltamivir).
   - Concomitant use for drugs excreted in urine via glomerular filtration and tubular secretion via the anionic pathway.
   - Pregnancy.

g. Note: There are no current studies among persons with hepatic dysfunction, underlying respiratory or cardiac disease. Seizure events have been reported during postmarketing use of zanamivir and oseltamivir although no epidemiologic studies have reported any increased risk for seizures with either zanamivir or oseltamivir use. For a more detailed description on dosing, drug-drug interactions, side effects and contraindications of the use of anti-influenza drugs, see Appendix 6, page 18. Also consult the package inserts for these drugs.
References and Other Sources of Information


Appendix 1. Sample Influenza Declination Form

Declination of Influenza Vaccination

My employer ___________________________, has offered that I receive influenza vaccination in order to protect myself and the patients I serve.

I acknowledge that I am aware of the following facts:

- Influenza vaccination is strongly recommended for me and all other healthcare workers to prevent influenza disease and its complications, including death.
- Due to my occupation, I may transmit influenza to my patients and other healthcare workers, as well as to my family and friends, even though I have no symptoms.
- If I become infected with influenza, even when my symptoms are mild, I can spread severe illness to others, particularly to those in this healthcare facility that are at high risk for influenza complications.
- I understand that the strains of virus that cause influenza infection change almost every year, which is why a different influenza vaccine is recommended each year.
- I have received education about the effectiveness of influenza vaccination as well as possible adverse events.
- I cannot get the influenza disease from the influenza vaccine.
- I understand that if I have not been vaccinated, by declining this vaccine, I continue to be at risk of acquiring influenza, which could endanger my health and the health of those with whom I have contact, including
  - patients in this healthcare facility
  - my coworkers
  - my family
  - my community

I have been given the opportunity to be immunized with influenza vaccine at no charge to myself. However, I decline influenza vaccination at this time.

I understand that I may change my mind at any time and accept influenza vaccination, if vaccine is available.

I have read and fully understand the information on this declination form.

Signature: __________________________________________ Date: ______________
Name (print): __________________________________________
### Appendix 2. Sample Case Log of Residents with Acute Respiratory Illness and/or Pneumonia

<table>
<thead>
<tr>
<th>Resident identification</th>
<th>Resident location</th>
<th>Vaccination status</th>
<th>Illness description</th>
<th>Influenza test results</th>
<th>Pneumococcal test results</th>
<th>Antivirals</th>
<th>Antibiotics</th>
<th>Illness outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Age</td>
<td>Sex (M/F)</td>
<td>Building</td>
<td>Unit</td>
<td>Room #, Bed designation</td>
<td>Influenza (Y/N)</td>
<td>Pneumonia (Y/N)</td>
<td>Date onset Illness</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Highest temperature</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cough (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Malaise (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chest congestion (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Purulent sputum (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nasal Congestion (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sore throat (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pneumonia (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CXR confirmed (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rapid antigen (+/-/ND)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Viral culture</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gram stain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sputum culture</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Date started/Date ended</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Influenza (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pneumonia (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hospitalized (Y/N)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Days hospitalized</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Died (Y/N, if yes, date)</td>
</tr>
</tbody>
</table>
### Appendix 3. Sample Case Log of Staff with Acute Respiratory Illness and/or Pneumonia

<table>
<thead>
<tr>
<th>Staff identification</th>
<th>Staff position and location</th>
<th>Influenza Vaccine status</th>
<th>Illness description</th>
<th>Influenza test results</th>
<th>Antiviral drugs</th>
<th>Illness outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Age</td>
<td>Position</td>
<td>Location</td>
<td>Influenza (Y/N)</td>
<td>Date onset</td>
<td>Date resolved</td>
</tr>
<tr>
<td></td>
<td>Date of illness</td>
<td></td>
<td>Cough (Y/N)</td>
<td>Nasal Congestion (Y/N)</td>
<td>Highest temperature</td>
<td>Date returned to work</td>
</tr>
<tr>
<td></td>
<td>Malaise (Y/N)</td>
<td></td>
<td>Chills (Y/N)</td>
<td>Date started</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sore throat (Y/N)</td>
<td>Date ended</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aches (joint, etc) (Y/N)</td>
<td>Rapid antigen (+/-/ND)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Viral culture</td>
<td>Date started</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Date ended</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix 4. Sample Summary Log of Acute Respiratory Illness and Pneumonia

From: Month, day, year To: Month, day, year

Enter the number of persons with the indicated symptoms, test results, and illness outcomes, as indicated

<table>
<thead>
<tr>
<th>Location</th>
<th>Vaccination status of ill persons</th>
<th>Summary of symptoms</th>
<th>Influenza test results</th>
<th>Pneumococcal test Results</th>
<th>Antibiotics</th>
<th>Antivirals</th>
<th>Illness outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area within the facility (building, wing, unit, etc)</td>
<td>No. vaccinated: influenza</td>
<td>No. vaccinated: PPV</td>
<td>Temp &gt;99°F</td>
<td>Cough</td>
<td>Malaise</td>
<td>Chest congestion</td>
<td>Purulent sputum</td>
</tr>
<tr>
<td>Area within the facility (building, wing, unit, etc)</td>
<td>No. vaccinated: influenza</td>
<td>No. vaccinated: PPV</td>
<td>Temp &gt;99°F</td>
<td>Cough</td>
<td>Malaise</td>
<td>Chest congestion</td>
<td>Purulent sputum</td>
</tr>
</tbody>
</table>

From Reference 2.
Appendix 5. Sample Line List of Residents with Adverse Reactions to Anti-Influenza Medication

<table>
<thead>
<tr>
<th>Resident identification</th>
<th>Resident location</th>
<th>Respiratory illness</th>
<th>Antiviral drug/dosing</th>
<th>Adverse reaction</th>
<th>Actions taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Age</td>
<td>Sex (M/F)</td>
<td>Building</td>
<td>Unit</td>
<td>Room#</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

From Reference 2.
Appendix 6. Antiviral Drugs
(from Reference 1; reference numbers below refer to Reference 1 references)

Although annual vaccination is the primary strategy for preventing complications of influenza virus infections, antiviral medications with activity against influenza viruses can be effective for the chemoprophylaxis and treatment of influenza. Four licensed influenza antiviral agents are available in the United States: amantadine, rimantadine, zanamivir, and oseltamivir. Influenza A virus resistance to amantadine and rimantadine can emerge rapidly during treatment. On the basis of antiviral testing results conducted at CDC and in Canada indicating high levels of resistance (23,24,284), ACIP recommends that neither amantadine nor rimantadine be used for the treatment or chemoprophylaxis of influenza A in the United States until susceptibility to these antiviral medications has been re-established among circulating influenza A viruses. Oseltamivir or zanamivir can be prescribed if antiviral treatment of influenza is indicated. Oseltamivir is approved for treatment of persons aged ≥1 year, and zanamivir is approved for treatment of persons aged ≥7 years. Oseltamivir and zanamivir can be used for chemoprophylaxis of influenza; oseltamivir is licensed for use in persons aged ≥1 year, and zanamivir is licensed for use in persons aged ≥5 years.

Antiviral Agents for Influenza
Zanamivir and oseltamivir are chemically related antiviral drugs known as neuraminidase inhibitors that have activity against both influenza A and B viruses. Both zanamivir and oseltamivir were approved in 1999 for treatment of uncomplicated influenza virus infections. In 2000, oseltamivir was approved for chemoprophylaxis of influenza among persons aged ≥13 years and was approved for chemoprophylaxis of children aged ≥1 year in 2005. In 2006, zanamivir was approved for chemoprophylaxis of children aged ≥5 years.

The two drugs differ in pharmacokinetics, side effects, routes of administration, approved age groups, dosages, and costs. An overview of the indications, use, administration, and known primary side effects of these medications is presented in the following sections. Package inserts should be consulted for additional information. Detailed information regarding amantadine and rimantadine is available in the previous publication of the ACIP influenza recommendations (285).

Role of Laboratory Diagnosis
Appropriate treatment of patients with respiratory illness depends on accurate and timely diagnosis. Influenza surveillance information and diagnostic testing can aid clinical judgment and help guide treatment decisions. For example, early diagnosis of influenza can reduce the inappropriate use of antibiotics and provide the option of using antiviral therapy. However, because certain bacterial infections can produce symptoms similar to influenza, bacterial infections should be considered and appropriately treated, if suspected. In addition, bacterial infections can occur as a complication of influenza.

The accuracy of clinical diagnosis of influenza on the basis of symptoms alone is limited because symptoms from illness caused by other pathogens can overlap considerably with influenza (33,42,43). Because testing all patients who might have influenza is not feasible, influenza surveillance by state and local health departments and CDC can provide information regarding the presence of influenza viruses in the community. Surveillance also can identify the predominant circulating types, influenza A subtypes, and strains of influenza viruses.

Diagnostic tests available for influenza include viral culture, serology, rapid antigen testing, polymerase chain reaction (PCR), and immunofluorescence assays (28). The sensitivity and specificity of any test for influenza can vary by the laboratory that performs the test, the type of test used, the type of specimen tested, and the timing of specimen collection. Among respiratory specimens for viral isolation or rapid detection, nasopharyngeal specimens are typically more effective than throat swab specimens (286). As with any diagnostic test, results should be evaluated in the context of other clinical and epidemiologic information available to health-care providers.

Commercial rapid diagnostic tests are available that can detect influenza viruses in 30 minutes (28,287). Some tests are approved for use in any outpatient setting, whereas others must be used in a moderately complex clinical laboratory. These rapid tests differ in the types of influenza viruses they can detect and whether they can distinguish between influenza types. Different tests can detect 1) only influenza A viruses;
2) both influenza A and B viruses, but not distinguish between the two types; or 3) both influenza A and B and distinguish between the two.

None of the rapid tests provide any information regarding influenza A subtypes. The types of specimens acceptable for use (i.e., throat, nasopharyngeal, or nasal; and aspirates, swabs, or washes) also vary by test. The specificity and, in particular, the sensitivity of rapid tests are lower than for viral culture and vary by test (288,289). Because of the lower sensitivity of the rapid tests, physicians should consider confirming negative tests with viral culture or other means because of the possibility of false-negative rapid test results, especially during periods of peak community influenza activity. In contrast, false-positive rapid test results are less likely but can occur during periods of low influenza activity. Therefore, when interpreting results of a rapid influenza test, physicians should consider the positive and negative predictive values of the test in the context of the level of influenza activity in their community. Package inserts and the laboratory performing the test should be consulted for more details regarding use of rapid diagnostic tests. Additional information concerning diagnostic testing is available at http://www.cdc.gov/flu/professionals/labdiagnosis.htm. Despite the availability of rapid diagnostic tests, collecting clinical specimens for viral culture is critical because only culture isolates can provide specific information regarding circulating strains and subtypes of influenza viruses. This information is needed to compare current circulating influenza strains with vaccine strains, to guide decisions regarding influenza treatment and chemoprophylaxis, and to formulate vaccine for the coming year. Virus isolates also are needed to monitor the emergence of antiviral resistance and the emergence of novel influenza A subtypes that might pose a pandemic threat.

**Antiviral Drug-Resistant Strains of Influenza Virus**

CDC recently reported that 193 (92%) of 209 influenza A (H3N2) viruses isolated from patients in 26 states demonstrated a change at amino acid 31 in the M2 gene that confers resistance to adamantanes (23,24). In addition, two of eight influenza A (H1N1) viruses tested were resistant (24). Canadian health authorities also have reported the same mutation in a comparable proportion of isolates recently tested (284). Until these findings, previous screenings of epidemic strains of influenza A viruses found few amantadine- and rimantadine-resistant viruses (290--292).

Viral resistance to adamantanes can emerge rapidly during treatment because a single point mutation at amino acid positions 26, 27, 30, 31, or 34 of the M2 protein can confer cross resistance to both amantadine and rimantadine (293,294). Drug-resistant viruses can emerge in approximately one third of patients when either amantadine or rimantadine is used for therapy (293,295,296). During the course of amantadine or rimantadine therapy, resistant influenza strains can replace susceptible strains within 2--3 days of starting therapy (290,297). Resistant viruses have been isolated from persons who live at home or in an institution in which other residents are taking or have taken amantadine or rimantadine as therapy (298,299); however, the frequency with which resistant viruses are transmitted and their effect on efforts to control influenza are unknown.

Persons who have influenza A virus infection and who are treated with either amantadine or rimantadine can shed susceptible viruses early in the course of treatment and later shed drug-resistant viruses, including after 5--7 days of therapy (295).

Resistance to zanamivir and oseltamivir can be induced in influenza A and B viruses in vitro (300--307), but induction of resistance usually requires multiple passages in cell culture. By contrast, resistance to amantadine and rimantadine in vitro can be induced with fewer passages in cell culture (308,309).

Development of viral resistance to zanamivir and oseltamivir during treatment has been identified but does not appear to be frequent (310--314). In one pediatric study, 5.5% of patients treated with oseltamivir had posttreatment isolates that were resistant to neuraminidase inhibitors. One small study of Japanese children treated with oseltamivir reported a high frequency of resistant viruses (315). However, no transmission of neuraminidase inhibitor-resistant viruses in humans has been documented to date. No isolates with reduced susceptibility to zanamivir have been reported from clinical trials, although the number of posttreatment isolates tested is limited (316), and the risk for emergence of zanamivir-resistant isolates cannot be quantified (317). Only one clinical isolate with reduced susceptibility to zanamivir, obtained from an immunocompromised child on prolonged therapy, has been reported (312). Available diagnostic tests are not optimal for detecting clinical resistance to the neuraminidase inhibitor antiviral drugs, and additional tests are being developed (316,318). Postmarketing surveillance for neuraminidase inhibitor-resistant influenza viruses is being conducted (319).
Indications for Use of Antivirals When Susceptibility Exists

Treatment
When administered within 2 days of illness onset to otherwise healthy adults, zanamivir and oseltamivir can reduce the duration of uncomplicated influenza A and B illness by approximately 1 day compared with placebo (91, 320–334). More clinical data are available concerning the efficacy of zanamivir and oseltamivir for treatment of influenza A virus infection than for treatment of influenza B virus infection (324, 335–344). However, in vitro data and studies of treatment among mice and ferrets (345–352), in addition to clinical studies, have documented that zanamivir and oseltamivir have activity against influenza B viruses (310, 317, 325, 329, 353, 354).

Data are limited regarding the effectiveness of the antiviral agents in preventing serious influenza-related complications (e.g., bacterial or viral pneumonia or exacerbation of chronic diseases). Evidence for the effectiveness of these antiviral drugs is principally based on studies of patients with uncomplicated influenza (355). Data are limited concerning the effectiveness of zanamivir and oseltamivir for treatment of influenza among persons at high risk for serious complications of influenza (31, 321, 322, 324, 325, 330–338). Among influenza virus infected participants in 10 clinical trials, the risk for pneumonia among those participants receiving oseltamivir was approximately 50% lower than among those persons receiving a placebo (339). A similar significant reduction was also found for hospital admissions; a 50% reduction was observed in the small subset of high-risk participants, although this reduction was not statistically significant. Fewer studies of the efficacy of influenza antivirals have been conducted among pediatric populations (295, 322, 328, 329). One study of oseltamivir treatment documented a decreased incidence of otitis media among children (323).

Inadequate data exist regarding the safety and efficacy of any of the influenza antiviral drugs for use among children aged <1 year (289).

Initiation of antiviral treatment within 2 days of illness onset is recommended. The recommended duration of treatment with either zanamivir or oseltamivir is 5 days.

Chemoprophylaxis
Chemoprophylactic drugs are not a substitute for vaccination, although they are critical adjuncts in preventing and controlling influenza. In community studies of healthy adults, both oseltamivir and zanamivir are similarly effective in preventing febrile, laboratory-confirmed influenza illness (efficacy: zanamivir, 84%; oseltamivir, 82%) (324, 340, 356). Both antiviral agents also have been reported to prevent influenza illness among persons administered chemoprophylaxis after a household member had influenza diagnosed (341, 353, 356). Experience with chemoprophylactic use of these agents in institutional settings or among patients with chronic medical conditions is limited in comparison with the adamantanes (310, 337, 338, 342–344). One 6-week study of oseltamivir chemoprophylaxis among nursing home residents reported a 92% reduction in influenza illness (310, 357). Use of zanamivir has not been reported to impair the immunologic response to influenza vaccine (317, 358). Data are not available regarding the efficacy of any of the four antiviral agents in preventing influenza among severely immunocompromised persons.

When determining the timing and duration for administering influenza antiviral medications for chemoprophylaxis, factors related to cost, compliance, and potential side effects should be considered. To be maximally effective as chemoprophylaxis, the drug must be taken each day for the duration of influenza activity in the community.

Persons at High Risk Who Are Vaccinated After Influenza Activity Has Begun. Persons at high risk for complications of influenza still can be vaccinated after an outbreak of influenza has begun in a community. However, development of antibodies in adults after vaccination takes approximately 2 weeks (265, 266).

When influenza vaccine is administered while influenza viruses are circulating, chemoprophylaxis should be considered for persons at high risk during the time from vaccination until immunity has developed. Children aged <9 years who receive influenza vaccine for the first time can require 6 weeks of chemoprophylaxis (i.e., chemoprophylaxis for 4 weeks after the first dose of vaccine and an additional 2 weeks of chemoprophylaxis after the second dose).

Persons Who Provide Care to Those at High Risk. To reduce the spread of virus to persons at high risk during community or institutional outbreaks, chemoprophylaxis during peak influenza activity can be considered for unvaccinated persons who have frequent contact with persons at high risk. Persons with frequent contact include employees of hospitals, clinics, and chronic-care facilities; household members; visiting nurses; and volunteer workers. If an outbreak is caused by a strain of influenza that might not be covered by the vaccine, chemoprophylaxis should be considered for all such persons, regardless of their vaccination status.
**Persons Who Have Immune Deficiencies.** Chemoprophylaxis can be considered for persons at high risk who are expected to have an inadequate antibody response to influenza vaccine. This category includes persons infected with HIV, chiefly those with advanced HIV disease. No published data are available concerning possible efficacy of chemoprophylaxis among persons with HIV infection or interactions with other drugs used to manage HIV infection. Such patients should be monitored closely if chemoprophylaxis is administered.

**Other Persons.** Chemoprophylaxis throughout the influenza season or during peak influenza activity might be appropriate for persons at high risk who should not be vaccinated. Chemoprophylaxis also can be offered to persons who wish to avoid influenza illness. Health-care providers and patients should make this decision on an individual basis.

**Control of Influenza Outbreaks in Institutions**

Using antiviral drugs for treatment and chemoprophylaxis of influenza is a key component of influenza outbreak control in institutions. In addition to antiviral medications, other outbreak-control measures include instituting droplet precautions and establishing cohorts of patients with confirmed or suspected influenza, reoffering influenza vaccinations to unvaccinated staff and patients, restricting staff movement between wards or buildings, and restricting contact between ill staff or visitors and patients (359--361) (see Additional Information Regarding Influenza Virus Infection Control Among Specific Populations).

The majority of published reports concerning use of antiviral agents to control influenza outbreaks in institutions are based on studies of influenza A outbreaks among nursing home populations that received amantadine or rimantadine (335,362--366). Less information is available concerning use of neuraminidase inhibitors in influenza A or B institutional outbreaks (337,338,344,357,367). When confirmed or suspected outbreaks of influenza occur in institutions that house persons at high risk, chemoprophylaxis should be started as early as possible to reduce the spread of the virus. In these situations, having preapproved orders from physicians or plans to obtain orders for antiviral medications on short notice can substantially expedite administration of antiviral medications.

When outbreaks occur in institutions, chemoprophylaxis should be administered to all residents, regardless of whether they received influenza vaccinations during the previous fall, and should continue for a minimum of 2 weeks. If surveillance indicates that new cases continue to occur, chemoprophylaxis should be continued until approximately 1 week after the end of the outbreak. The dosage for each resident should be determined individually. Chemoprophylaxis also can be offered to unvaccinated staff members who provide care to persons at high risk. Chemoprophylaxis should be considered for all employees, regardless of their vaccination status, if the outbreak is suspected to be caused by a strain of influenza virus that is not well-matched to the vaccine.

In addition to nursing homes, chemoprophylaxis also can be considered for controlling influenza outbreaks in other closed or semiclosed settings (e.g., dormitories or other settings in which persons live in close proximity).

To limit the potential transmission of drug-resistant virus during outbreaks in institutions, whether in chronic or acute-care settings or other closed settings, measures should be taken to reduce contact as much as possible between persons taking antiviral drugs for treatment and other persons, including those taking chemoprophylaxis (see Antiviral Drug-Resistant Strains of Influenza Virus).

**Dosage**

Dosage recommendations vary by age group and medical conditions (Table 1).

**Children**

**Zanamivir.** Zanamivir is approved for treatment of influenza among children aged ≥7 years. The recommended dosage of zanamivir for treatment of influenza is two inhalations (one 5-mg blister per inhalation for a total dose of 10 mg) twice daily (approximately 12 hours apart); the chemoprophylaxis dosage of zanamivir for children aged >5 years is 10 mg (two inhalations) once a day (317).

**Oseltamivir.** Oseltamivir is approved for treatment and chemoprophylaxis among persons aged ≥1 year. Recommended treatment and chemoprophylaxis dosages of oseltamivir for children vary by the weight of the child. The treatment dosage recommendation of oseltamivir for children who weigh <15 kg is 30 mg twice a day; for children weighing 15--23 kg, 45 mg twice a day; for those weighing 23--40 kg, 60 mg twice a day; and for those weighing >40 kg, 75 mg twice a day (310). The chemoprophylaxis recommended dosage of oseltamivir for children weighing ≤15 kg is 30 mg once a day; for those weighing 15--23 kg, 45 mg once a day; for those weighing >23--40 kg, 60 mg once a day; and for those weighing >40 kg, 75 mg once a day.

**Persons Aged ≥65 Years**
Zanamivir and Oseltamivir. No reduction in dosage is recommended on the basis of age alone.

**Persons with Impaired Renal Function**

Zanamivir. Limited data are available regarding the safety and efficacy of zanamivir for patients with impaired renal function. Among patients with renal failure who were administered a single intravenous dose of zanamivir, decreases in renal clearance, increases in half-life, and increased systemic exposure to zanamivir were observed (317,368). However, a limited number of healthy volunteers who received high doses of zanamivir intravenously tolerated systemic levels of zanamivir that were substantially higher than those resulting from administration of zanamivir by oral inhalation at the recommended dose (369,370). On the basis of these considerations, the manufacturer recommends no dose adjustment for inhaled zanamivir for a 5-day course of treatment for patients with either mild-to-moderate or severe impairment in renal function (317).

Oseltamivir. Serum concentrations of oseltamivir carboxylate, the active metabolite of oseltamivir, increase with declining renal function (310,371). For patients with creatinine clearance of 10–30 mL/min (310), a reduction of the treatment dosage of oseltamivir to 75 mg once daily and in the chemoprophylaxis dosage to 75 mg every other day is recommended. No treatment or chemoprophylaxis dosing recommendations are available for patients undergoing routine renal dialysis treatment.

**Persons with Liver Disease**

Zanamivir and Oseltamivir. Neither of these medications has been studied among persons with hepatic dysfunction.

**Persons with Seizure Disorders**

Zanamivir and Oseltamivir. Seizure events have been reported during postmarketing use of zanamivir and oseltamivir, although no epidemiologic studies have reported any increased risk for seizures with either zanamivir or oseltamivir use.

**Route**

Oseltamivir is administered orally in capsule or oral suspension form. Zanamivir is available as a dry powder that is self-administered via oral inhalation by using a plastic device included in the package with the medication. Patients will benefit from instruction and demonstration of correct use of this device.

**Pharmacokinetics**

**Zanamivir**

In studies of healthy volunteers, approximately 7%–21% of the orally inhaled zanamivir dose reached the lungs, and 70%–87% was deposited in the oropharynx (317,372). Approximately 4%–17% of the total amount of orally inhaled zanamivir is systemically absorbed. Systemically absorbed zanamivir has a half-life of 2.5–5.1 hours and is excreted unchanged in the urine. Unabsorbed drug is excreted in the feces (317,370).

**Oseltamivir**

Approximately 80% of orally administered oseltamivir is absorbed systemically (371). Absorbed oseltamivir is metabolized to oseltamivir carboxylate, the active neuraminidase inhibitor, primarily by hepatic esterases. Oseltamivir carboxylate has a half-life of 6–10 hours and is excreted in the urine by glomerular filtration and tubular secretion via the anionic pathway (310,373). Unmetabolized oseltamivir also is excreted in the urine by glomerular filtration and tubular secretion (325).

**Side Effects and Adverse Reactions**

When considering use of influenza antiviral medications (i.e., choice of antiviral drug, dosage, and duration of therapy), clinicians must consider the patient's age, weight, and renal function (Table 1); presence of other medical conditions; indications for use (i.e., chemoprophylaxis or treatment); and the potential for interaction with other medications.

**Zanamivir**

In a study of zanamivir treatment of ILI among persons with asthma or chronic obstructive pulmonary disease where study medication was administered after use of a B2-agonist, 13% of patients receiving zanamivir and 14% of patients who received placebo (inhaled powdered lactose vehicle) experienced a >20% decline in forced expiratory volume in 1 second (FEV1) after treatment (317,330). However, in a phase I study of persons with mild or moderate asthma who did not have ILI, one of 13 patients experienced bronchospasm after administration of zanamivir (317). In addition, during postmarketing surveillance, cases
of respiratory function deterioration after inhalation of zanamivir have been reported. Certain patients had underlying airway disease (e.g., asthma or chronic obstructive pulmonary disease). Because of the risk for serious adverse events and because the efficacy has not been demonstrated among this population, zanamivir is not recommended for treatment for patients with underlying airway disease (317). If physicians decide to prescribe zanamivir to patients with underlying chronic respiratory disease after carefully considering potential risks and benefits, the drug should be used with caution under conditions of appropriate monitoring and supportive care, including the availability of short-acting bronchodilators (355). Patients with asthma or chronic obstructive pulmonary disease who use zanamivir are advised to 1) have a fast-acting inhaled bronchodilator available when inhaling zanamivir and 2) stop using zanamivir and contact their physician if they experience difficulty breathing (317). No definitive evidence is available regarding the safety or efficacy of zanamivir for persons with underlying respiratory or cardiac disease or for persons with complications of acute influenza (355). Allergic reactions, including oropharyngeal or facial edema, also have been reported during postmarketing surveillance (317,337).

In clinical treatment studies of persons with uncomplicated influenza, the frequencies of adverse events were similar for persons receiving inhaled zanamivir and for those receiving placebo (i.e., inhaled lactose vehicle alone) (320--325,337). The most common adverse events reported by both groups were diarrhea; nausea; sinusitis; nasal signs and symptoms; bronchitis; cough; headache; dizziness; and ear, nose, and throat infections. Each of these symptoms was reported by <5% of persons in the clinical treatment studies combined (317).

**Oseltamivir**

Nausea and vomiting were reported more frequently among adults receiving oseltamivir for treatment (nausea without vomiting, approximately 10%; vomiting, approximately 9%) than among persons receiving placebo (nausea without vomiting, approximately 6%; vomiting, approximately 3%) (310,326,327,374). Among children treated with oseltamivir, 14% had vomiting, compared with 8.5% of placebo recipients. Overall, 1% discontinued the drug secondary to this side effect (329), whereas a limited number of adults who were enrolled in clinical treatment trials of oseltamivir discontinued treatment because of these symptoms (310). Similar types and rates of adverse events were reported in studies of oseltamivir chemoprophylaxis (310). Nausea and vomiting might be less severe if oseltamivir is taken with food (317,310).

**Use During Pregnancy**

No clinical studies have been conducted regarding the safety or efficacy of zanamivir or oseltamivir for pregnant women. Because of the unknown effects of influenza antiviral drugs on pregnant women and their fetuses, these two drugs should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus. Oseltamivir and zanamivir are both "Pregnancy Category C" medications (see manufacturers' package inserts) (317,375).

**Drug Interactions**

Clinical data are limited regarding drug interactions with zanamivir. However, no known drug interactions have been reported, and no clinically critical drug interactions have been predicted on the basis of in vitro data and data from studies using rats (310,373).

Limited clinical data are available regarding drug interactions with oseltamivir. Because oseltamivir and oseltamivir carboxylate are excreted in the urine by glomerular filtration and tubular secretion via the anionic pathway, a potential exists for interaction with other agents excreted by this pathway. For example, coadministration of oseltamivir and probenecid resulted in reduced clearance of oseltamivir carboxylate by approximately 50% and a corresponding approximate twofold increase in the plasma levels of oseltamivir carboxylate (304,367).

No published data are available concerning the safety or efficacy of using combinations of any of these influenza antiviral drugs. For more detailed information concerning potential drug interactions for any of these influenza antiviral drugs, package inserts should be consulted.

**Table 1:** (use Table 6 in MMWR) Recommended daily dosage of influenza medications for treatment and chemoprophylaxis
Table 1. Recommended adult\(^1\) daily dosage of antiviral medication for treatment and prophylaxis

<table>
<thead>
<tr>
<th>Antiviral agent</th>
<th>Age Group(^1)</th>
<th>13-64 years</th>
<th>&gt;65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zanamivir(^2)</td>
<td>Treatment</td>
<td>10 mg (two inhalations) twice daily</td>
<td>10 mg (two inhalations) twice daily</td>
</tr>
<tr>
<td>Oseltamivir(^3)</td>
<td>Treatment</td>
<td>75 mg twice daily</td>
<td>75 mg twice daily</td>
</tr>
<tr>
<td></td>
<td>Prophylaxis</td>
<td>75 mg once daily</td>
<td>75 mg once daily</td>
</tr>
</tbody>
</table>

\(^1\) Dosage for children available from Reference 1

\(^2\) Zanamivir is administered via inhalation using a plastic device included in the package with the medication. Patients will benefit from instruction and demonstration of the correct use of the device. Zanamivir is not recommended for those persons with underlying airway disease.

\(^3\) A reduction in the dose of oseltamivir is recommended for persons with creatinine clearance <30 mL/min.